Comparing two forms of a study drug in healthy men
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study compares how the body absorbs a drug called belumosudil when given as a liquid versus a tablet. It aims to see if the two forms are similar, which could help decide the best way to give the drug in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a healthy man between 18 and 45 years old
- Weigh between 110 and 253 pounds, with a body mass index between 18 and 32
- Be willing to use contraception during the study
- Have no major health problems, recent infections, or allergies
- Not smoke more than 5 cigarettes a week and be able to stop during the study
- Avoid certain medications, supplements, and vaccinations before the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called belumosudil for people who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see how safe the drug is. You may qualify if you have already tried at least two other treatments and are currently on a stable steroid dose.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
This study tests a new medicine called belumosudil for people who have chronic graft-versus-host disease (cGVHD) that has not improved with at least two earlier treatments. It compares belumosudil to other available treatments to see which works better and is safer.
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.